SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-13-002192
Filing Date
2013-03-01
Accepted
2013-03-01 16:05:42
Documents
11
Period of Report
2013-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pdli20130228_8k.htm 8-K 29338
2 EXHIBIT 99.1 pdli20130228_8kex99-1.htm EX-99 165953
3 EXHIBIT 99.2 pdli20130228_8kex99-2.htm EX-99 3965
4 EXHIBIT 99.3 pdli20130228_8kex99-3.htm EX-99 854701
5 logo.jpg GRAPHIC 23080
6 a6.jpg GRAPHIC 205973
7 a5.jpg GRAPHIC 167785
8 a4.jpg GRAPHIC 246458
9 a3.jpg GRAPHIC 159372
10 a2.jpg GRAPHIC 312925
11 a1.jpg GRAPHIC 225832
  Complete submission text file 0001437749-13-002192.txt   2904158
Mailing Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451
Business Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451 775-832-8500
PDL BIOPHARMA, INC. (Filer) CIK: 0000882104 (see all company filings)

IRS No.: 943023969 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19756 | Film No.: 13657636
SIC: 2836 Biological Products, (No Diagnostic Substances)